Discontinued — last reported Q1 '26
Pharmaceutical — SG&A
Merck & Co. Pharmaceutical — SG&A decreased by 13.9% to $1.33B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.0%, from $1.40B to $1.33B. Over 3 years (FY 2022 to FY 2025), Pharmaceutical — SG&A shows relatively stable performance with a 2.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
High spending may be necessary for new product launches, but excessive levels relative to sales can indicate operational inefficiency.
Detailed definition
Operating expenses related to marketing, sales force support, legal, and general corporate overhead allocated to the pha...
Peer comparison
Varies based on the stage of the product lifecycle and the intensity of marketing required for key therapeutic areas.
mrk_segment_pharmaceutical_segment_selling_general_and_administrativeHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.37B | $1.37B | $1.37B | $1.37B | $1.48B | $1.48B | $1.48B | $1.48B | $1.43B | $1.51B | $1.52B | $1.67B | $1.40B | $1.46B | $1.47B | $1.55B | $1.33B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +7.8% | +0.0% | +0.0% | +0.0% | -3.2% | +5.9% | +0.3% | +9.7% | -15.8% | +3.9% | +0.9% | +5.3% | -13.9% |
| YoY Change | — | — | — | — | +7.8% | +7.8% | +7.8% | +7.8% | -3.2% | +2.6% | +2.9% | +12.9% | -1.9% | -3.8% | -3.3% | -7.1% | -5.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s pharmaceutical — sg&a?
- Merck & Co. (MRK) reported pharmaceutical — sg&a of $1.33B in Q1 2026.
- How has Merck & Co.'s pharmaceutical — sg&a changed year-over-year?
- Merck & Co.'s pharmaceutical — sg&a decreased by 5.0% year-over-year, from $1.40B to $1.33B.
- What is the long-term trend for Merck & Co.'s pharmaceutical — sg&a?
- Over 3 years (2022 to 2025), Merck & Co.'s pharmaceutical — sg&a has grown at a 2.4% compound annual growth rate (CAGR), from $5.47B to $5.87B.
- What does pharmaceutical — sg&a mean?
- The overhead and commercial costs required to run the pharmaceutical business.